⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 15, 2025

Supplemental Table 6 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy

Leanne G. Ahronian Soumyadip Sahu Minjie Zhang Ayushi S. Patel Ke Geng Reshmee Bhattacharya Gerald S. Falchook Jonathan W. Goldman Alexander I. Spira Salman R. Punekar David R. Spigel Judy S. Wang Ferdinandos Skoulidis Janaye Stephens Mary Meynardie Jaylen M. Powell Alfonso Lopez Michela Ranieri Magdalena A. Ploszaj Yi Jer Tan Yeuan Ting Lee Yi Yu Jiehui Deng Ting Chen Patrick McCarren Alice Tsai Suleman S. Hussain Brian Doyon Kenjie Amemiya Jacques Ermolieff Preksha Shahagadkar Nikitha M. Das Lauren R. Flynn Julie A. Shields Laney Danielczyk Brian J. McMillan Andre Mignault Samuel R. Meier Hsin‐Jung Wu David J. Guerin Douglas A. Whittington Chengyin Min Iga Sienczylo John P. Maxwell Heather DiBenedetto Hideo Watanabe Brian B. Haines Alan Huang Adam Crystal Jannik N. Andersen Xinyuan Wu Kwok‐Kin Wong

View at Publisher

Ask AI

Bookmark

Share

Key Points

Patients with STK11-deficient tumors showed improved sensitivity to anti–PD-1 immunotherapy with CoREST inhibitors.
Biopsies from 10 STK11-mutant patients provided crucial data on therapeutic response and tumor characteristics.
This Phase 1 study highlights the potential of small-molecule inhibitors to enhance immunotherapy effects in specific tumor types.
Findings suggest that targeting CoREST may offer new avenues for treating STK11-deficient tumors.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Phase 1 trial assessed paired biopsies from 10 patients with STK11-deficient tumors, indicating improved immunotherapy outcomes.

Abstract

10 patients with STK11-deficient solid tumors enrolled in NCT05887492 provided paired biopsies during Phase 1

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ahronian et al. (2025) studied this question.

synapsesocial.com/papers/68f199bfde32064e504dcab8 https://doi.org/10.1158/0008-5472.30363262

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Table 2 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
2Supplemental Table 1 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
3Supplemental Figure 6 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
4Supplemental Table 3 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
5Supplemental Figure 5 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
6Supplemental Table 4 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
7Supplemental Figure 9 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025
8Supplemental Table 5 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy2025